AMA council looks at clinical research now
Article Abstract:
The Council on Scientific Affairs of the American Medical Association sponsored a two-day workshop in 1996 to analyze the effect that managed care will have on clinical research. Many medical treatments arise from clinical research and many physicians are concerned that the cost-cutting practices of managed care will eliminate research. However, not all managed care programs are alike. Those formed not as for-profit enterprises but as organizations concerned about patient outcomes are more likely to fund clinical research. The Group Health Cooperative of Puget Sound, which has been in existence since the 1940s, has an $8 million budget for research. Managed care programs are ideal settings in which to do research because they have an easily accessible group of physicians and patients.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Exciting potential of DNA vaccines explored
Article Abstract:
Immunization using a DNA carrier is the newest concept in vaccine development and may soon be used in medical practices. By injecting the gene sequence for a desired antigen in plasmid DNA into the body, a strong immune response is evoked. Diseases such as HIV, hepatitis, and tuberculosis may be prevented. The current method uses weakened forms of bacteria and viruses to trigger an immune response. Nucleic acid is easily stored and is injected in a saline solution. The main safety problems include ensuring that the DNA does not damage the host's set of genes and immunological tolerance does not not develop. Besides generating an immune response, autoimmune disorders and cancer may be treated with nucleic acid.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1995
User Contributions:
Comment about this article or add new information about this topic:
FDA funding problems imperil safety of biological products in the United States
Article Abstract:
The Food and Drug Administration (FDA) may need more funding to review many of the products that the biotechnology industry will create. This is the function of the FDA's Center for Biologics Evaluation and Research (CBER), but the center's 1998 budget is half what it was in 1995 and one-third of the research positions will be eliminated by the year 2000. To counteract this financial crunch, Congress passed a law requiring manufacturers to pay a users' fee, which in 1996 made up one-third of CBER's budget. The 1997 FDA Modernization Act also contains money for research.
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Freedom to meet local clinical needs. The burden of chronic wounds in the UK. People should pay for a percentage of their healthcare
- Abstracts: A randomized multicenter trial assessing a home uterine activity monitoring device used in the absence of daily nursing contact
- Abstracts: A randomized multicenter trial assessing a home uterine activity monitoring device used in the absence of daily nursing contact. part 2
- Abstracts: More expertise needed in death investigations. 'Decent research and closure' needed on medical marijuana, says head of NIH panel
- Abstracts: A multicommunity trial for primary prevention of adolescent drug abuse: effects on drug use prevalence. Long-term follow-up results of a randomized drug abuse prevention trial in a white middle-class population